Ravasio, R.; Cranmer, H.; Kearns , I.; Viti, R.; Corinti, S. Cost-Utility Analysis of Brigatinib Compared to Alectinib in the Treatment of ALK-Positive NSCLC in Patients Previously Not Treated With an ALK Inhibitor. AboutOpen 2022, 9, 92-104.